{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:52:41Z","timestamp":1791363161262,"version":"4.3.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Oncol. Rev."],"abstract":"<jats:p>Ovarian cancer remains a major cause of gynaecological cancer mortality, largely because early disease is frequently asymptomatic and reliable population-based screening remains unavailable. Systemic inflammation is increasingly recognised as an important component of ovarian cancer biology, linking tumour progression, immune dysregulation, angiogenesis, metastasis and treatment resistance. This narrative review critically evaluates blood-based inflammatory biomarkers, including C-reactive protein, interleukin-6, interleukin-8, tumour necrosis factor-\u03b1, fibrinogen, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, systemic immune-inflammation index (SII), systemic inflammation response index (SIRI) and pan-immune-inflammation value (PIV), across early detection, metastatic assessment, treatment decision-making and prognostic stratification. Available evidence indicates that elevated inflammatory indices are consistently associated with advanced disease and adverse outcomes, although substantial heterogeneity exists in biomarker thresholds, populations, timing of measurement and analytical approaches. Recent evidence also suggests that preoperative NLR and SII may contribute to treatment selection, including neoadjuvant chemotherapy, although prognostic independence is not consistently demonstrated. Importantly, inflammatory biomarkers lack sufficient specificity for standalone ovarian cancer screening and should not replace CA-125, HE4, imaging or histopathological assessment. Their greatest clinical potential lies in multimarker models integrating systemic inflammatory, tumour-specific, molecular and clinical variables. Future research should prioritise prospective multicentre validation, standardised thresholds, longitudinal assessment and clinically interpretable prediction models to determine whether inflammatory profiling can advance precision risk stratification and treatment selection in ovarian cancer.<\/jats:p>","DOI":"10.3389\/or.2026.1914468","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:29:11Z","timestamp":1791361751000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Blood-based inflammatory biomarkers in ovarian cancer: addressing the challenge of early detection, metastasis, and prognostic stratification"],"prefix":"10.3389","volume":"20","author":[{"given":"Emmanuel Ifeanyi","family":"Obeagu","sequence":"first","affiliation":[{"name":"Division of Haematology, Department of Biomedical and Laboratory Science, Africa University","place":["Mutare, Zimbabwe"]},{"name":"Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand","place":["Johannesburg, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3390\/diagnostics15040406","article-title":"Early diagnosis of ovarian cancer: a comprehensive review of the advances, challenges, and future directions","volume":"15","author":"Hong","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3322\/caac.20113","article-title":"Recent progress in the diagnosis and treatment of ovarian cancer","volume":"61","author":"Jelovac","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.2147\/CMAR.S555874","article-title":"Clear cell ovarian carcinoma and its distinct coagulopathy profile: molecular drivers and clinical implications","volume":"17","author":"Obeagu","year":"2025","journal-title":"Cancer Manag Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1097\/MS9.0000000000002926","article-title":"Leukocyte dynamics in female reproductive health: roles and mechanisms","volume":"87","author":"Obeagu","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3390\/cells14070488","article-title":"The role of inflammation in cancer: mechanisms of tumor initiation, progression, and metastasis","volume":"14","author":"Nishida","year":"2025","journal-title":"Cells"},{"key":"B6","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2147\/JIR.S503479","article-title":"Inflammation and immune escape in ovarian cancer: pathways and therapeutic opportunities","volume":"18","author":"Liu","year":"2025","journal-title":"J Inflamm Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e92239","DOI":"10.7759\/cureus.92239","article-title":"Association of chronic inflammation-associated cancer with cytokines","volume":"17","author":"Nakase","year":"2025","journal-title":"Cureus"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.3390\/diagnostics15151942","article-title":"The role of systemic immune-inflammation index (SII) in diagnosing pediatric acute appendicitis","volume":"15","author":"Firinci","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.3390\/ijms26083868","article-title":"The relationship between Neutrophil-to-Lymphocyte ratio, Platelet-to-Lymphocyte ratio, and systemic immune-inflammation index markers and response to biological therapy in patients with psoriasis","volume":"26","author":"Kimak-Pielas","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5937\/jomb0-46035","article-title":"The prognostic and clinical value of neutrophil-to-lymphocyte ratio (NLR) in ovarian cancer: a systematic review and meta-analysis","volume":"43","author":"Zhang","year":"2024","journal-title":"J Med Biochem"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.31557\/APJCP.2024.25.6.1921","article-title":"Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as an early prognostic marker in patients with ovarian cancer: a systematic review and meta-analysis","volume":"25","author":"Winata","year":"2024","journal-title":"Asian Pac J Cancer Prev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1543055","DOI":"10.3389\/fonc.2025.1543055","article-title":"Combined CA125, NSE, and multiple inflammatory indices for diagnosis of oral squamous cell carcinoma","volume":"15","author":"Abudukelimu","year":"2025","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3390\/life13081689","article-title":"Tumor markers and their diagnostic significance in ovarian cancer","volume":"13","author":"Matsas","year":"2023","journal-title":"Life (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e70407","DOI":"10.1002\/cnr2.70407","article-title":"The evaluation of diagnostic, prognostic, and predictive role of hematologic inflammatory indices NLR, PLR, and LMR in common solid tumors","volume":"8","author":"Arianmanesh","year":"2025","journal-title":"Cancer Rep (Hoboken)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3390\/cancers10080251","article-title":"The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer","volume":"10","author":"Savant","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.3390\/cancers17101691","article-title":"Interleukin-6 is a crucial factor in shaping the inflammatory tumor microenvironment in ovarian cancer and determining its hot or cold nature with diagnostic and prognostic utilities","volume":"17","author":"Amer","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"149185","DOI":"10.1155\/2014\/149185","article-title":"Chronic inflammation and cytokines in the tumor microenvironment","volume":"2014","author":"Landskron","year":"2014","journal-title":"J Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e70103","DOI":"10.1111\/apm.70103","article-title":"Role of systemic inflammatory markers in the differential diagnosis of organizing pneumonia and lung cancer","volume":"133","author":"Erinanc","year":"2025","journal-title":"APMIS"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2217\/fon.09.90","article-title":"Mechanisms of the epithelial-mesenchymal transition by TGF-Beta","volume":"5","author":"Wendt","year":"2009","journal-title":"Future Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13048-025-01864-3","article-title":"Vascular endothelial generating factor pathway in ovarian cancer","volume":"18","author":"Zhao","year":"2025","journal-title":"J Ovarian Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejcsup.2019.11.003","article-title":"The hallmarks of ovarian cancer: focus on angiogenesis and micro-environment and new models for their characterisation","volume":"15","author":"Heredia-Soto","year":"2020","journal-title":"EJC Suppl"},{"key":"B22","doi-asserted-by":"publisher","first-page":"694821","DOI":"10.3389\/fonc.2021.694821","article-title":"Inexpensive systemic inflammatory biomarkers in ovarian cancer: an umbrella systematic review of 17 prognostic meta-analyses","volume":"11","author":"El","year":"2021","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.3390\/cancers17122001","article-title":"Blood-based biomarkers as predictive and prognostic factors in immunotherapy-treated patients with solid tumors-currents and perspectives","volume":"17","author":"Kaczmarek","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e17475","DOI":"10.1097\/MD.0000000000017475","article-title":"Prognostic significance of neutrophil-lymphocyte ratio (NLR) in patients with ovarian cancer: a systematic review and meta-analysis","volume":"98","author":"Yin","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1002\/mco2.350","article-title":"The role of platelets in the regulation of tumor growth and metastasis: the mechanisms and targeted therapy","volume":"4","author":"Liao","year":"2023","journal-title":"MedComm"},{"key":"B26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s40001-023-01342-w","article-title":"The critical role of platelet in cancer progression and metastasis","volume":"28","author":"Zhou","year":"2023","journal-title":"Eur J Med Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"595835","DOI":"10.3389\/fimmu.2020.595835","article-title":"C-Reactive protein and cancer-diagnostic and therapeutic insights","volume":"11","author":"Hart","year":"2020","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12967-018-1638-9","article-title":"The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor","volume":"16","author":"Xie","year":"2018","journal-title":"J Transl Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e22964","DOI":"10.1002\/jcla.22964","article-title":"Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab","volume":"33","author":"Liu","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.3390\/cancers12123730","article-title":"CA125 and ovarian cancer: a comprehensive review","volume":"12","author":"Charkhchi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1646276","DOI":"10.3389\/fimmu.2025.1646276","article-title":"NLR (neutrophil to lymphocyte ratio), PLR (platelet to lymphocyte ratio), and SII (systemic immune-inflammation index) reflect disease activity and renal remission in patients with lupus nephritis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.3748\/wjg.v12.i23.3746","article-title":"Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus","volume":"12","author":"Gockel","year":"2006","journal-title":"World J Gastroenterol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3946320231178769","DOI":"10.1177\/03946320231178769","article-title":"Systemic inflammation factors as survival prognosis markers in ovarian neoplasm and the relationship with cancer-associated inflammatory mediators-a review","volume":"37","author":"Dinca","year":"2023","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00404-018-4678-8","article-title":"Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies","volume":"297","author":"Zhao","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12885-018-4318-5","article-title":"Prognostic value of systemic inflammatory markers in ovarian cancer: a PRISMA-compliant meta-analysis and systematic review","volume":"18","author":"Zhu","year":"2018","journal-title":"BMC Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e16429","DOI":"10.7759\/cureus.16429","article-title":"Pretreatment Neutrophil-to-Lymphocyte ratio: a prognostic biomarker of survival in patients with epithelial ovarian cancer","volume":"13","author":"John-Olabode","year":"2021","journal-title":"Cureus"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2147\/IJWH.S496137","article-title":"Systemic inflammatory biomarkers as a predictive markers for ovarian cancer","volume":"17","author":"Kurniadi","year":"2025","journal-title":"Int J Womens Health"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.7150\/jca.112768","article-title":"Differential diagnosis of benign and malignant ovarian tumors with combined tumor and systemic inflammation-related markers","volume":"16","author":"Song","year":"2025","journal-title":"J Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1381268","DOI":"10.3389\/fonc.2024.1381268","article-title":"Comparison of the diagnostic efficacy of systemic inflammatory indicators in the early diagnosis of ovarian cancer","volume":"14","author":"Song","year":"2024","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13048-023-01106-4","article-title":"Combined use of CA125, neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio for the diagnosis of borderline and malignant epithelial ovarian tumors","volume":"16","author":"Huang","year":"2023","journal-title":"J Ovarian Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1498007","DOI":"10.3389\/fneur.2025.1498007","article-title":"The clinical value of the neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, monocyte-to-lymphocyte ratio and platelet-to-lymphocyte ratio for predicting the severity of patients with autoimmune encephalitis","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Neurol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.7150\/jca.46446","article-title":"Systemic immune-inflammation index (SII): a more promising Inflammation-based prognostic marker for patients with synchronic colorectal peritoneal carcinomatosis","volume":"11","author":"Yan","year":"2020","journal-title":"J Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/1471-2407-11-210","article-title":"Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients","volume":"11","author":"Lane","year":"2011","journal-title":"BMC Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1102\/1470-7330.2013.9003","article-title":"Incorporating prognostic imaging biomarkers into clinical practice","volume":"13","author":"Phillip","year":"2013","journal-title":"Cancer Imaging"},{"key":"B45","doi-asserted-by":"publisher","first-page":"17588359241233225","DOI":"10.1177\/17588359241233225","article-title":"Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4","volume":"16","author":"Ghose","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/diagnostics11030465","article-title":"New predictive biomarkers for ovarian cancer","volume":"11","author":"Atallah","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3390\/cancers17071124","article-title":"The role of the systemic immune-inflammation index in predicting postoperative complications in ovarian cancer patients: a retrospective cohort study","volume":"17","author":"K\u00f6se","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.3390\/cancers15225429","article-title":"C-Reactive protein as an early predictor of efficacy in advanced non-small-cell lung cancer patients: a tumor dynamics-biomarker modeling framework","volume":"15","author":"Nassar","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.22034\/APJCP.2018.19.10.2687","article-title":"Targeting inflammation in ovarian cancer through natural antioxidants, potential therapeutic and preventive implications","volume":"19","author":"Singh","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.3390\/biology14111487","article-title":"Explainable artificial intelligence for ovarian cancer: biomarker contributions in ensemble models","volume":"14","author":"Ucuzal","year":"2025","journal-title":"Biology (Basel)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s11845-026-04407-x","article-title":"Systemic inflammatory markers are associated with neoadjuvant chemotherapy selection but not survival in advanced serous epithelial ovarian cancer","volume":"195","author":"Yalcin","year":"2026","journal-title":"Ir J Med Sci"}],"container-title":["Oncology Reviews"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1914468\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:29:12Z","timestamp":1791361752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1914468\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":51,"alternative-id":["10.3389\/or.2026.1914468"],"URL":"https:\/\/doi.org\/10.3389\/or.2026.1914468","relation":{},"ISSN":["1970-5557"],"issn-type":[{"value":"1970-5557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1914468"}}